Literature DB >> 25972264

Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.

Thomas P Kole1, Michael Tong1, Binbin Wu1, Siyuan Lei1, Olusola Obayomi-Davies1, Leonard N Chen1, Simeng Suy1, Anatoly Dritschilo1, Ellen Yorke2, Sean P Collins1.   

Abstract

BACKGROUND: Late urinary symptom flare has been shown to occur in a small subset of men treated with ultra- hypofractionated stereotactic body radiotherapy (SBRT) for prostate cancer. The purpose of this study was to use normal tissue complication probability modeling in an effort to derive SBRT specific dosimetric predictor's of late urinary flare.
MATERIAL AND METHODS: Two hundred and sixteen men were treated for localized prostate cancer using ultra- hypofractionated SBRT. A dose of 35-36.25 Gy in 5 fractions was delivered to the prostate and proximal seminal vesicles. Functional surveys were conducted before and after treatment to assess late toxicity. Phenomenologic NTCP models were fit to bladder DVHs and late urinary flare outcomes using maximum likelihood estimation.
RESULTS: Twenty-nine patients experienced late urinary flare within two years of completion of treatment. Fitting of bladder DVH data to a Lyman NTCP model resulted in parameter estimates of m, TD50, and n of 0.19 (0-0.47), 38.7 Gy (31.1-46.4), and 0.13 (-0.14-0.41), respectively. Subsequent fit to a hottest volume probit model revealed a significant association of late urinary flare with dose to the hottest 12.7% of bladder volume. Multivariate analysis resulted in a final model that included patient age and hottest volume probit model predictions. Kaplan-Meier analysis demonstrated a two-year urinary flare free survival of 95.7% in patients 65 years or older with a bladder D12.7% of 33.5 Gy or less, compared to 74.5% in patients meeting none of these criteria.
CONCLUSION: NTCP modeling of late urinary flare after ultra-hypofractionated prostate SBRT demonstrates a relatively small volume effect for dose to the bladder, suggesting that reduction of volume receiving elevated dose will result in decreased incidence of late urinary toxicity. Future studies will be needed to examine the impact of dose to other potential sources of late genitourinary toxicity.

Entities:  

Mesh:

Year:  2015        PMID: 25972264      PMCID: PMC4986047          DOI: 10.3109/0284186X.2015.1037011

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  23 in total

1.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

2.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.

Authors:  Raymond Miralbell; Stephen A Roberts; Eduardo Zubizarreta; Jolyon H Hendry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-15       Impact factor: 7.038

3.  Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.

Authors:  Christopher R King; James D Brooks; Harcharan Gill; Joseph C Presti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-06       Impact factor: 7.038

4.  Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial.

Authors:  Sean M McBride; Douglas S Wong; John J Dombrowski; Bonnie Harkins; Patricia Tapella; Heather N Hanscom; Sean P Collins; Irving D Kaplan
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

5.  Long-term urinary sequelae following 125iodine prostate brachytherapy.

Authors:  Juanita Crook; Neil Fleshner; Chris Roberts; Greg Pond
Journal:  J Urol       Date:  2007-11-12       Impact factor: 7.450

6.  Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up.

Authors:  Mira Keyes; Stacy Miller; Veronika Moravan; Tom Pickles; Mitchell Liu; Ingrid Spadinger; Vincent Lapointe; W James Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-11       Impact factor: 7.038

7.  Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.

Authors:  Evelyn Elias; Joelle Helou; Liying Zhang; Patrick Cheung; Andrea Deabreu; Laura D'Alimonte; Perakaa Sethukavalan; Alexandre Mamedov; Marlene Cardoso; Andrew Loblaw
Journal:  Radiother Oncol       Date:  2014-07-05       Impact factor: 6.280

8.  Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.

Authors:  Jennifer A Woo; Leonard N Chen; Aditi Bhagat; Eric K Oermann; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Deepak Kumar; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Front Oncol       Date:  2014-05-26       Impact factor: 6.244

9.  Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Authors:  Leonard N Chen; Simeng Suy; Sunghae Uhm; Eric K Oermann; Andrew W Ju; Viola Chen; Heather N Hanscom; Sarah Laing; Joy S Kim; Siyuan Lei; Gerald P Batipps; Keith Kowalczyk; Gaurav Bandi; John Pahira; Kevin G McGeagh; Brian T Collins; Pranay Krishnan; Nancy A Dawson; Kathryn L Taylor; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2013-03-13       Impact factor: 3.481

10.  Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.

Authors:  Alan J Katz; Michael Santoro; Fred Diblasio; Richard Ashley
Journal:  Radiat Oncol       Date:  2013-05-13       Impact factor: 3.481

View more
  8 in total

1.  Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response.

Authors:  Kyle Wang; Panayiotis Mavroidis; Trevor J Royce; Aaron D Falchook; Sean P Collins; Stephen Sapareto; Nathan C Sheets; Donald B Fuller; Issam El Naqa; Ellen Yorke; Jimm Grimm; Andrew Jackson; Ronald C Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-12-22       Impact factor: 7.038

2.  Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.

Authors:  Michael C Repka; Shan Guleria; Robyn A Cyr; Thomas M Yung; Harsha Koneru; Leonard N Chen; Siyuan Lei; Brian T Collins; Pranay Krishnan; Simeng Suy; Anatoly Dritschilo; John Lynch; Sean P Collins
Journal:  Front Oncol       Date:  2016-05-18       Impact factor: 6.244

3.  Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy.

Authors:  Luca F Valle; Dan Ruan; Audrey Dang; Rebecca G Levin-Epstein; Ankur P Patel; Joanne B Weidhaas; Nicholas G Nickols; Percy P Lee; Daniel A Low; X Sharon Qi; Christopher R King; Michael L Steinberg; Patrick A Kupelian; Minsong Cao; Amar U Kishan
Journal:  Front Oncol       Date:  2020-05-20       Impact factor: 6.244

4.  A case-control study using motion-inclusive spatial dose-volume metrics to account for genito-urinary toxicity following high-precision radiotherapy for prostate cancer.

Authors:  Oscar Casares-Magaz; Ludvig P Muren; Niclas Pettersson; Maria Thor; Austin Hopper; Rick Knopp; Joseph O Deasy; Michael Væth; John Einck; Vitali Moiseenko
Journal:  Phys Imaging Radiat Oncol       Date:  2018-10-05

5.  Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer.

Authors:  Sarthak Shah; Tamir Sholklapper; Michael Creswell; Abigail Pepin; Jonathan Cantalino; Ryan Andrew Hankins; Simeng Suy; Sean P Collins
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

6.  Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking.

Authors:  Raffaella Lucchini; Denis Panizza; Riccardo Ray Colciago; Veronica Vernier; Martina Camilla Daniotti; Valeria Faccenda; Stefano Arcangeli
Journal:  Radiat Oncol       Date:  2021-09-17       Impact factor: 3.481

7.  Comparison of Late Urinary Symptoms Following SBRT and SBRT with IMRT Supplementation for Prostate Cancer.

Authors:  Li Rebekah Feng; Simeng Suy; Sean P Collins; Jonathan W Lischalk; Berwin Yuan; Leorey N Saligan
Journal:  Curr Urol       Date:  2018-03-30

Review 8.  A Narrative Review on the Pathophysiology and Management for Radiation Cystitis.

Authors:  C Browne; N F Davis; E Mac Craith; G M Lennon; D W Mulvin; D M Quinlan; Gerard P Mc Vey; D J Galvin
Journal:  Adv Urol       Date:  2015-12-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.